Risk of new-onset diabetes with high-intensity statin use

Lancet Diabetes Endocrinol. 2024 Sep;12(9):612-613. doi: 10.1016/S2213-8587(24)00217-1.

Authors

David M Diamond¹, Kevin E Kip²

Affiliations

¹ Department of Psychology, University of South Florida, Tampa, FL 33620, USA. Electronic address: [email protected].
² Health Services Division, Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

PMID: 39174155
DOI: 10.1016/S2213-8587(24)00217-1

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus / drug therapy
Diabetes Mellitus / epidemiology
Diabetes Mellitus, Type 2 / drug therapy
Diabetes Mellitus, Type 2 / epidemiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Risk Factors

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors